SUMMARY A randomised, double blind, placebo controlled, crossover study of digoxin withdrawal and reintroduction was carried out over two periods of eight weeks each after long term treatment. Forty four patients with stable heart failure in sinus rhythm and plasma digoxin concentrations over 0-8 ng/ml were studied. We decided, therefore, to carry out a randomised double blind, placebo controlled, crossover study of the effects of withdrawal and reintroduction of digoxin after long term treatment for heart failure in sinus rhythm, investigating simultaneously a range of different measures of the effects of digoxin clinically, haemodynamically, and pharmacologically.
When William Withering first used digitalis in the successful treatment ofdropsy over 200 years ago, his practice was to give it for short periods of time.' This century the usefulness of digitalis as a positive inotropic drug in the treatment of heart failure was rediscovered, but it has been modern practice to use it for indefinite periods.
In recent years, however, the practice of continuing treatment indefinitely with digitalis in heart failure in sinus rhythm has been questioned. For example, in several studies it has been shown that most although this finding has not been confirmed by others.7-'0 In addition, we and others have shown that the cellular pharmacological effects of digoxin, demonstrable in the erythrocytes ofpatients on short term digoxin treatment, are not found in patients on long term treatment, suggesting tolerance to the pharmacological effects of digoxin. 12 We decided, therefore, to carry out a randomised double blind, placebo controlled, crossover study of the effects of withdrawal and reintroduction of digoxin after long term treatment for heart failure in sinus rhythm, investigating simultaneously a range of different measures of the effects of digoxin clinically, haemodynamically, and pharmacologically.
Our purposes were to determine the relations among these different levels of effect of digoxin (fig 1) and whether any of these measurements could be used to 529 Pugh, White predict the clinical outcome after the withdrawal of digoxin.
The study was given the approval of the local ethics committee.
Patients and methods

PATIENTS
We studied 44 patients, all of whom fulfilled the following criteria: (a) digitalised for heart failure in sinus rhythm; (b) taking digoxin (Lanoxin, Wellcome) for at least three months; (c) no clinical evidence of digitalis toxicity; (d) steady state plasma digoxin concentrations (at least six hours after the previous dose) > 0-8 ng/ml (1 0 nmol/l) and < 2-0 ng/ ml (2-6 nmol/1). Table 1 shows the patients' ages, sex distribution, causes of heart failure, duration of treatment with digoxin, and other drug treatments.
Criteria for exclusion were: (a) atrial fibrillation; (b) plasma digoxin concentration < 0 8 ng/ml or > 2-0 ng/ml; (c) clinical evidence of fluid retention; (d) recent acute myocardial infarction (< 3 months before). Withdrawal and reintroduction of digoxin in heartfailure There were no exclusions based on other drug treatment, and wherever possible other drugs were continued in unchanging dosages throughout the study. Dosages of diuretics were increased during periods ofdeterioration when indicated (see Results). Figure 2 shows the study design. After the initial assessment the patients were randomised to treatment with either their usual dosage of digoxin (Lanoxin) or to an equal number of matched placebo tablets. After eight weeks of continuous treatment (period 1) the altemative treatment was given and continued for a further eight weeks (period 2). All the patients were then given digoxin again for a final eight weeks (period 3). We have designated those patients who were randomised to placebo first as group 1 and those who were randomised to digoxin first as group 2. When patients switched from placebo to digoxin treatment they were given three times the usual dose of digoxin on the first day only, as a loading dose. When they switched from digoxin to placebo extra placebo tablets were given to mimic a loading dose. Patients who "switched" from digoxin in period 2 to digoxin in period 3 A trial of exercise tolerance was performed in each patient before randomisation, on a treadmill with simultaneous electrocardiographic recording of resting and peak heart rates. A level of exercise at which the patient became dyspnoeic at or before 10 minutes was determined, and the rate of the treadmill was then reduced to the point at which the patient could just exercise for 10 minutes without dyspnoea. Thus any deterioration in exercise capacity was assessed by either the occurrence of dyspnoea during exercise or the patient's inability to complete the exercise test. Patients taking fi adrenoceptor antagonists were excluded from this assessment. Of the 11 who deteriorated while taking placebo, heart failure became worse in nine and two went into atrial fibrillation (both also with worsening heart failure). Of the five who deteriorated while taking digoxin, three developed worsening heart failure and two went into atrial fibrillation, but without heart failure. Among those who deteriorated, four patients had to be withdrawn from the study; of these, two deteriorated while taking placebo (one heart failure, one atrial fibrillation) and two deteriorated while taking digoxin (one heart failure, one atrial fibrillation). Worsening of heart failure while on placebo in those patients who were not withdrawn from the study was treated by increasing doses of diuretics, with a successful outcome in all but two cases, in whom heart failure resolved only on reintroduction of digoxin. In two patients worsening ofheart failure in sinus rhythm while on digoxin was successfully treated with increased dosages of diuretics. Table 4 shows the occurrence of deterioration in terms of the numbers of treatment periods during which deterioration did or did not occur. There were significantly more occasions on which deterioration occurred during placebo periods than during digoxin periods, both when the patients who developed atrial fibrillation are included (p < 0.04) and when they are not (p = 0.02).
DESIGN OF THE STUDY
SYSTOLIC TIME INTERVALS Figure 3 shows the systolic time intervals measured at five different times: (1) immediately before the withdrawal of digoxin; (2 and 3) after placebo Pugh, White, Aronson, Grahame-Smith, Bloomfield treatment for one week and eight weeks respectively; (4 and 5) after the reintroduction of digoxin for one week and eight weeks respectively.
The data were subdivided to compare those who deteriorated during a placebo period with those who did not deteriorate at all. In addition, the systolic time intervals at the time of deterioration are shown for those who deteriorated while they were taking placebo. There were too few data to allow conclusions about the changes in systolic time intervals in patients who deteriorated while taking digoxin.
In those who deteriorated during withdrawal of digoxin there was a significant increase in total electromechanical systole (QS2I) after withdrawal and a decrease after reintroduction. These changes in QS2I were attributable to similar changes in the preejection period (PEPI), and there were no significant changes in the left ventricular ejection time (LVETI) Non Withdrawal and reintroduction of digoxin in heartfailure or the ratio of PEP:LVET. Similar changes, but of smaller magnitude, were seen in patients who did not deteriorate at any time during the study. In contrast, the systolic time intervals (QS2I, LVETI, and PEPI) were all significantly higher at the time of deterioration than at entry into the study, and also, in the cases of QS2I and LVETI, than at the times of reintroduction of digoxin. However, the ratio PEP:LVET did not change during deterioration. Note that the values taken during the eighth week of placebo in those patients who deteriorated relate to patients whose clinical deterioration had, in most cases, been ameliorated by increases in dosages of diuretics. An analysis of this kind including all those who deteriorated at any time during the study showed exactly the same patterns ofchange as shown by those who deteriorated while on placebo. Figure 4 shows the changes in left ventricular internal diameter sizes during diastole (LVIDd) and during systole (LVID,) and the derived measures of ventricular contractility (fractional shortening and mean velocity of circumferen-tial fibre shortening (VCF)) during the study. There were no changes in any of these echocardiographic measurements. In contrast with the systolic time intervals, however, we do not have any echocardiographic measurements in deteriorators at the time of deterioration.
ECHOCARDIOGRAPHY
EXERCISE HEART RATES
There were no changes in either resting heart rates just before exercise or peak heart rates during exercise, after either the withdrawal or the reintroduction of digoxin in any of the patients (data not illustrated). tent with rebound from the effects of digoxin, and after eight weeks these had both returned to the values found before withdrawal. After the reintroduction of digoxin there were no changes in either binding or uptake. Figure 5 shows the changes in intraerythrocytic sodium concentration during the withdrawal and reintroduction of digoxin. In those who did not deteriorate there was no change in intraerythrocytic sodium concentrations after digoxin withdrawal, but a significant increase after its reintroduction, an increase which persisted at eight weeks. In the deteriorators there was both a fall in intraerythrocytic sodium concentrations after the withdrawal of digoxin and an increase after its reintroduction.
Thus a comparison of deteriorators and nondeteriorators showed differences in the pattems of change in all three pharmacological measurements after the withdrawal and reintroduction of digoxin.
Discussion
We know of five previous randomised, double blind, We therefore compared haemodynamic and pharmacological changes after the withdrawal of digoxin with the clinical consequences of withdrawal, and in particular we compared those patients in whom withdrawal resulted in clinical deterioration with those in whom it did not.
OCCURRENCE OF CLINICAL DETERIORATION DURING THE STUDY
To determine the occurrence of deterioration during the period of study we used a scoring system similar to those previously used by others,701 7 and designed to detect changes in both signs and symptoms. We defined deterioration quite stringently, requiring a Pugh, White, Aronson, Grahame-Smith, Bloomfield consistent increase in total score of at least two points, and a worsening of at least one sign of cardiac failure. In those whom we considered not to have deteriorated clinically (a judgement that was reached before the analysis of the other data), though there were occasional increases of one or two points in the scores relating to symptoms, these were not consistently present during the relevant study period, and required no changes in treatment.
The results show firstly that by these criteria most patients (64%) did not have evidence of clinical deterioration during the study, and secondly that when deterioration occurred it did so in some cases (11%) despite the continuing presence of digoxin. In only 25% of patients did clinical deterioration occur after digoxin withdrawal. Even then we found it possible to control worsening heart failure simply by increasing the dose of diuretics, and in only two patients (5%) did we find that cardiac failure did not resolve until digoxin was reintroduced. In two other patients digoxin was required to control fast atrial fibrillation which occurred during placebo treatment.
Thus although the proportion of patients deteriorating during our study (36%) was similar to that previously found by others,23 in only 25% of cases was deterioration directly attributable to a loss of the beneficial effect of digoxin rather than to deterioration caused by the natural course of cardiac failure, and in only four cases (9%) was reintroduction of digoxin necessary.
Two of the four patients who developed atrial fibrillation during the study did so while taking digoxin (plasma digoxin concentrations 1.6 and 1-3 ng/ml). This is consistent with the widespread belief that digoxin may not be useful in preventing atrial fibrillation (for example in paroxysmal atrial fibrillation). Withdrawal and reintroduction of digoxin in heartfailure effect, there was no significant change in PEP:LVET. This is consistent with our previous observations that although total electromechanical systole and LVETI shorten significantly when heart failure responds to treatment with digoxin, the ratio of PEP:LVET does not alter.14 By the end of the eighth week ofplacebo treatment in these patients, who had deteriorated after withdrawal of digoxin, there was clinical improvement in cardiac function caused by the administration of increased dosages of diuretics, and in consequence the LVETI once again shortened (fig 3, right hand  panel) . This is also consistent with the lack of overall change in echocardiographic measurements over the same period of time. None the less, at that time there was still significant lengthening of the QS2I and PEPI, indicative of the continuing absence of the effects of digoxin. In the patients who had not deteriorated (fig 3, middle panel) there was no change in myocardial contractility, as assessed by the LVETI and echocardiographic measurements, but there was none the less evidence ofa loss ofthe effects of digoxin, as assessed by increases in QS2I and PEPI. These changes were smaller than the changes seen in the patients who deteriorated while on placebo, but nevertheless they suggest that digoxin was exerting a pharmacodynamic effect on the heart that was not contributing to the control of heart failure in these patients, and which could therefore be lost after withdrawal without consequent deterioration of the patients' clinical state.
After the reintroduction of digoxin the systolic time intervals QS2I and PEPI shortened in both groups, showing that the heart was still responsive to the electrophysiological effects of digoxin. In contrast, there was no overall change in LVETI or PEP/ LVET in either group. This suggests that in patients in whom diuretic treatment has been successful in relieving the signs and symptoms of heart failure, digitalis has little to offer in the way of additional positive inotropic support. In patients who deteriorated, the fall in LVETI from the time of deterioration to the time of reintroduction of digoxin may be attributable to improvement in left ventricular function secondary to increases in diuretic dosages.
CHANGES IN EXERCISE TESTING DURING WITHDRAWAL
We were unable to carry out exercise testing at every visit, and therefore could not detect any changes in exercise capacity or peak heart rate during exercise at times of deterioration. By the eighth week of placebo treatment the exercise responses were unchanged, even in those who had previously deteriorated clinically, presumably because of the increases in diuretic dosages. This observation is consistent with the finding of others that digoxin does not improve exercise tolerance in patients in whom diuretics have been used to produce a stable body weight. ' There are clearly differences in the patterns ofchange during withdrawal and reintroduction of digoxin when those who deteriorated are compared with those who did not. Two features of these patterns are particularly noteworthy.
Firstly, in those who deteriorated, but not in those who did not, withdrawal of digoxin was associated with a rebound in both ['H]-digoxin binding and uptake of rubidium-86, both of which rose at one week after withdrawal and then retumed to prewithdrawal values after eight weeks. This suggests that in those who deteriorated the effects ofdigoxin in occupying sodium/potassium pump sites, and thus in inhibiting transport, were lost during withdrawal. This was accompanied at one week by a fall in intraerythrocytic sodium concentration. If that also happened in the heart it could have been responsible for the loss oftherapeutic effect seen in these patients, by causing secondary changes in calcium disposition in the opposite direction from the changes that have been postulated to occur as part of the positive inotropic action of digitalis."9 Secondly, after the reintroduction ofdigoxin in the non-deteriorators, but not in the deteriorators, there was a fall in binding and uptake and at eight weeks a return to the values found before reintroduction.
This shows that the sodium/potassium pump sites in the erythrocytes ofthese patients were still capable of both responding to the pharmacological effects of digoxin and of adapting to those effects, as we have previously shown."
It is not clear to us why rebound after withdrawal did not occur in those who did not deteriorate nor why there was no evidence of a pharmacological effect on the erythrocytes after reintroduction in those who did deteriorate. It may be that there is a difference in the time course of effects in the two groups, and that we have failed to detect changes because we took samples only at one and eight weeks. Alternatively, it may be that other mechanisms participate in the control of the numbers and activity ofNa/K-ATPase sites on the erythrocyte membrane, and that these differ in deteriorators and nondeteriorators. For example, an endogenous inhibitor of the sodium/potassium pump, with a different rate of turnover in the two groups, could have produced differential results. The fact that the intraerythrocytic sodium concentrations showed different pat-terns of change from the two other pharmacological measurements suggests that other factors may have played a part.
PREDICTION OF DETERIORATION BEFORE WITHDRAWAL
It would clearly be ofvalue to have a measurement or observation in patients on long term digoxin treatment that would help to predict whether or not deterioration might be expected after digoxin withdrawal. However, none of the measurements we made at the time of entering patients into the study proved of value in discriminating between those patients who subsequently deteriorated and those who did not (table 3) . This finding is consistent with the findings of other workers who were unable to relate the outcome ofwithdrawal to any one of several measures, including age, sex, New York Heart Association class, the use of diuretics, the previous duration of digoxin treatment, the cause of the heart disease, and cardiac rhythm.710 In one study the presence of a third heart sound was found to be a good predictor of deterioration,6presumably since it reflects relatively poor left ventricular contraction. None of our patients had a third heart sound at entry to the study and we cannot therefore make any conclusions about that. Patients with plasma digoxin concentrations below 0-8 ng/ml are very unlikely to deteriorate after digoxin withdrawal,4 20 but this could not have contributed to our results since we studied patients with plasma digoxin concentrations > 0-8 ng/ml at entry to the study, and during digoxin treatment periods used dosages of digoxin which kept the plasma concentrations above 0-8 ng/ml.
It is clear from the results of this and other studies that digoxin continues to exert a beneficial effect in some patients with heart failure in sinus rhythm.
There are, however, no clear-cut criteria to predict which patients will deteriorate after digoxin withdrawal. Nevertheless, it is possible to formulate guidelines for the use of digoxin in the long term management of heart failure in sinus rhythm:
(a) If a patient is in a stable condition and has a plasma digoxin concentration below 0-8 ng/ml digoxin withdrawal is very likely to be safe. It has been suggested by others that this applies to patients not only in sinus rhythm but also in atrial fibrillation.420 (b) If a patient is in a stable condition, has a plasma digoxin concentration > 08 ng/ml, and is not at great risk of toxicity, digoxin withdrawal is probably not worth while, because there is a 25% risk ofdeterioration.
(c) If, however, there is an increased risk ofdigitalis toxicity (for example in a patient with deteriorating renal function, or in one who has difficulty in maintaining potassium balance) then careful withdrawal may be worth attempting.
(d) In a few patients (for example those with a third heart sound) it may be better to continue treatment, even when there is an increased risk of digitalis toxicity. In that case, however, monitoring of treatment should be increased to reduce the risk of toxicity.
Throughout this discussion we have assumed that digoxin treatment was thought to be appropriate in the first place, either alone or in addition to diuretics, vasodilators, or angiotensin converting enzyme inhibitors. As alternative forms of treatment become available the role of digitalis in the long term management of cardiac failure will undoubtedly evolve further.
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